Jing Wang

Jing Wang currently serves as the Co-Founder and CEO of Myro Therapeutics since June 2021. Prior experience includes holding the position of VP, Head of Translational Science at Constellation Pharmaceuticals from April 2019 to June 2021, and various senior roles at TESARO, Inc., including Sr. Director and Director of Translational Strategy and Research between April 2016 and April 2019. At Curis, Jing Wang led preclinical and translational biomarker efforts for a decade, beginning as a Senior Scientist and progressing to Director. Educational qualifications include a PhD in Medical Science from Harvard Medical School and a BS in Biophysics and Physiology from Peking University. Prior research experience includes a role as a Research Assistant at Peking University and a PhD candidacy at Harvard Medical School, focusing on neurodegeneration and pain modulation.